CIK 0001830487 · Large accelerated filer
Pharvaris N.V.
Sign in to watch- Ticker
- PHVS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Netherlands
- Entity type
- other
- Phone
- 31 (0)71 203 6410
- Business address
- J.H. OORTWEG 21, 2333 CH LEIDEN, LEIDEN, Netherlands
- Former names
- Pharvaris, B.V.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $20,335,217
- in 16 filings, $4.1M under 10b5-1 plans
Net −$20,335,217. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Schikan Johannes Gerardus Christiaan Petrus −$7.0M Director sold 64% of stake
- Lu Peng −$4.7M President sold 67% of stake
- Bjork Elisabeth −$2.0M Director sold 78% of stake
- Lesage Anne −$1.9M Chief Early Development sold 40% of stake
- Abele Stefan Andreas −$1.8M Chief Technical Ops Officer sold 54% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-29 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,700 | 12,772 | ||
| 2026-04-29 | Lu Peng Chief Medical Officer | Option exercise 10b5-1 | +3,733 | $2.59 | $10K | 69,816 |
| 2026-04-29 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −3,733 | $30.06 | $112K | 62,350 |
| 2026-04-29 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,733 | 234,474 | ||
| 2026-04-23 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −100 | $30.03 | $3K | 388,067 |
| 2026-04-23 | Lesage Anne Chief Early Development | Sale 10b5-1 | −100 | $30.03 | $3K | 156,869 |
| 2026-04-23 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +100 | $2.59 | $259 | 56,550 |
| 2026-04-23 | Lesage Anne Chief Early Development | Sale 10b5-1 | −100 | $30.03 | $3K | 56,450 |
| 2026-04-23 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100 | 15,872 | ||
| 2026-04-23 | Lu Peng Chief Medical Officer | Option exercise 10b5-1 | +100 | $2.59 | $259 | 66,183 |
| 2026-04-23 | Lu Peng Chief Medical Officer | Sale 10b5-1 | −100 | $30.03 | $3K | 66,083 |
| 2026-04-23 | Lu Peng Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −100 | 106,207 | ||
| 2026-04-22 | Schikan Johannes Gerardus Christiaan Petrus Director | Sale 10b5-1 | −7,000 | $30.05 | $210K | 388,167 |
| 2026-04-22 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +500 | $2.59 | $1K | 56,950 |
| 2026-04-22 | Lesage Anne Chief Early Development | Sale 10b5-1 | −500 | $30.00 | $15K | 56,450 |
| 2026-04-22 | Lesage Anne Chief Early Development | Option exercise 10b5-1 | +7,000 | $8.05 | $56K | 63,450 |
| 2026-04-22 | Lesage Anne Chief Early Development | Sale 10b5-1 | −7,000 | $30.05 | $210K | 56,450 |
| 2026-04-22 | Lesage Anne Chief Early Development | Sale 10b5-1 | −7,000 | $30.05 | $210K | 156,969 |
| 2026-04-22 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −500 | 15,972 | ||
| 2026-04-22 | Lesage Anne Chief Early Development | Option exercise · Stock Option (Right to Buy) 10b5-1 | −7,000 | 113,000 |
Page 8 of 9 · 170 trades